Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

DH vs HCAT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DH
Definitive Healthcare Corp.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$96M
5Y Perf.-97.8%
HCAT
Health Catalyst, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$113M
5Y Perf.-96.8%

DH vs HCAT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DH logoDH
HCAT logoHCAT
IndustryMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$96M$113M
Revenue (TTM)$238M$311M
Net Income (TTM)$-170M$-178M
Gross Margin76.0%48.7%
Operating Margin-15.6%-51.7%
Forward P/E5.5x14.1x
Total Debt$178M$20M
Cash & Equiv.$164M$51M

DH vs HCATLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DH
HCAT
StockSep 21May 26Return
Definitive Healthca… (DH)1002.2-97.8%
Health Catalyst, In… (HCAT)1003.2-96.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: DH vs HCAT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DH leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Health Catalyst, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
DH
Definitive Healthcare Corp.
The Income Pick

DH carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.71, yield 3.2%
  • Lower volatility, beta 1.71, Low D/E 46.9%, current ratio 1.64x
  • Beta 1.71, yield 3.2%, current ratio 1.64x
Best for: income & stability and sleep-well-at-night
HCAT
Health Catalyst, Inc.
The Growth Play

HCAT is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 1.5%, EPS growth -121.7%, 3Y rev CAGR 4.0%
  • -95.9% 10Y total return vs DH's -97.9%
  • 1.5% revenue growth vs DH's -4.2%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthHCAT logoHCAT1.5% revenue growth vs DH's -4.2%
ValueDH logoDHLower P/E (5.5x vs 14.1x)
Quality / MarginsHCAT logoHCAT-57.2% margin vs DH's -71.5%
Stability / SafetyDH logoDHBeta 1.71 vs HCAT's 2.05
DividendsDH logoDH3.2% yield; the other pay no meaningful dividend
Momentum (1Y)HCAT logoHCAT-59.9% vs DH's -66.1%
Efficiency (ROA)DH logoDH-24.5% ROA vs HCAT's -27.4%, ROIC -2.7% vs -32.9%

DH vs HCAT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DHDefinitive Healthcare Corp.
FY 2025
Subscription Services
96.2%$232M
Professional Services
3.8%$9M
HCATHealth Catalyst, Inc.
FY 2025
Recurring Technology
100.0%$208M

DH vs HCAT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDHLAGGINGHCAT

Income & Cash Flow (Last 12 Months)

DH leads this category, winning 5 of 6 comparable metrics.

HCAT and DH operate at a comparable scale, with $311M and $238M in trailing revenue. HCAT is the more profitable business, keeping -57.2% of every revenue dollar as net income compared to DH's -71.5%.

MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
RevenueTrailing 12 months$238M$311M
EBITDAEarnings before interest/tax$9M-$110M
Net IncomeAfter-tax profit-$170M-$178M
Free Cash FlowCash after capex$37M-$5M
Gross MarginGross profit ÷ Revenue+76.0%+48.7%
Operating MarginEBIT ÷ Revenue-15.6%-51.7%
Net MarginNet income ÷ Revenue-71.5%-57.2%
FCF MarginFCF ÷ Revenue+15.6%-1.5%
Rev. Growth (YoY)Latest quarter vs prior year-5.5%-6.2%
EPS Growth (YoY)Latest quarter vs prior year-38.9%-2.9%
DH leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

DH leads this category, winning 3 of 4 comparable metrics.
MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
Market CapShares × price$96M$113M
Enterprise ValueMkt cap + debt − cash$111M$82M
Trailing P/EPrice ÷ TTM EPS-0.71x-0.62x
Forward P/EPrice ÷ next-FY EPS est.5.50x14.15x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.25x
Price / SalesMarket cap ÷ Revenue0.40x0.36x
Price / BookPrice ÷ Book value/share0.26x0.45x
Price / FCFMarket cap ÷ FCF2.60x
DH leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

HCAT leads this category, winning 5 of 9 comparable metrics.

DH delivers a -48.1% return on equity — every $100 of shareholder capital generates $-48 in annual profit, vs $-55 for HCAT. HCAT carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to DH's 0.47x. On the Piotroski fundamental quality scale (0–9), HCAT scores 6/9 vs DH's 5/9, reflecting solid financial health.

MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
ROE (TTM)Return on equity-48.1%-54.7%
ROA (TTM)Return on assets-24.5%-27.4%
ROICReturn on invested capital-2.7%-32.9%
ROCEReturn on capital employed-2.7%-34.0%
Piotroski ScoreFundamental quality 0–956
Debt / EquityFinancial leverage0.47x0.08x
Net DebtTotal debt minus cash$14M-$31M
Cash & Equiv.Liquid assets$164M$51M
Total DebtShort + long-term debt$178M$20M
Interest CoverageEBIT ÷ Interest expense-5.53x-4.79x
HCAT leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HCAT leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in HCAT five years ago would be worth $299 today (with dividends reinvested), compared to $213 for DH. Over the past 12 months, HCAT leads with a -59.9% total return vs DH's -66.1%. The 3-year compound annual growth rate (CAGR) favors HCAT at -49.2% vs DH's -54.9% — a key indicator of consistent wealth creation.

MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
YTD ReturnYear-to-date-61.2%-30.3%
1-Year ReturnPast 12 months-66.1%-59.9%
3-Year ReturnCumulative with dividends-90.8%-86.9%
5-Year ReturnCumulative with dividends-97.9%-97.0%
10-Year ReturnCumulative with dividends-97.9%-95.9%
CAGR (3Y)Annualised 3-year return-54.9%-49.2%
HCAT leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DH and HCAT each lead in 1 of 2 comparable metrics.

DH is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than HCAT's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCAT currently trades 31.4% from its 52-week high vs DH's 19.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
Beta (5Y)Sensitivity to S&P 5001.71x2.05x
52-Week HighHighest price in past year$4.70$5.06
52-Week LowLowest price in past year$0.90$0.96
% of 52W HighCurrent price vs 52-week peak+19.6%+31.4%
RSI (14)Momentum oscillator 0–10040.563.9
Avg Volume (50D)Average daily shares traded317K720K
Evenly matched — DH and HCAT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates DH as "Hold" and HCAT as "Buy". Consensus price targets imply 239.5% upside for DH (target: $3) vs 57.2% for HCAT (target: $3). DH is the only dividend payer here at 3.20% yield — a key consideration for income-focused portfolios.

MetricDH logoDHDefinitive Health…HCAT logoHCATHealth Catalyst, …
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$3.13$2.50
# AnalystsCovering analysts1522
Dividend YieldAnnual dividend ÷ price+3.2%
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS$0.03
Buyback YieldShare repurchases ÷ mkt cap+51.3%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

DH leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). HCAT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.

Best OverallDefinitive Healthcare Corp. (DH)Leads 2 of 6 categories
Loading custom metrics...

DH vs HCAT: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is DH or HCAT a better buy right now?

For growth investors, Health Catalyst, Inc.

(HCAT) is the stronger pick with 1. 5% revenue growth year-over-year, versus -4. 2% for Definitive Healthcare Corp. (DH). Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — DH or HCAT?

Over the past 5 years, Health Catalyst, Inc.

(HCAT) delivered a total return of -97. 0%, compared to -97. 9% for Definitive Healthcare Corp. (DH). Over 10 years, the gap is even starker: HCAT returned -95. 9% versus DH's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — DH or HCAT?

By beta (market sensitivity over 5 years), Definitive Healthcare Corp.

(DH) is the lower-risk stock at 1. 71β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 20% more volatile than DH relative to the S&P 500. On balance sheet safety, Health Catalyst, Inc. (HCAT) carries a lower debt/equity ratio of 8% versus 47% for Definitive Healthcare Corp. — giving it more financial flexibility in a downturn.

04

Which is growing faster — DH or HCAT?

By revenue growth (latest reported year), Health Catalyst, Inc.

(HCAT) is pulling ahead at 1. 5% versus -4. 2% for Definitive Healthcare Corp. (DH). On earnings-per-share growth, the picture is similar: Definitive Healthcare Corp. grew EPS 63. 3% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HCAT leads at 4. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — DH or HCAT?

Health Catalyst, Inc.

(HCAT) is the more profitable company, earning -57. 2% net margin versus -57. 5% for Definitive Healthcare Corp. — meaning it keeps -57. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DH leads at -8. 5% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — DH leads at 75. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is DH or HCAT more undervalued right now?

On forward earnings alone, Definitive Healthcare Corp.

(DH) trades at 5. 5x forward P/E versus 14. 1x for Health Catalyst, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DH: 239. 5% to $3. 13.

07

Which pays a better dividend — DH or HCAT?

In this comparison, DH (3.

2% yield) pays a dividend. HCAT does not pay a meaningful dividend and should not be held primarily for income.

08

Is DH or HCAT better for a retirement portfolio?

For long-horizon retirement investors, Definitive Healthcare Corp.

(DH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 2% yield). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DH: -97. 9%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between DH and HCAT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DH is a small-cap income-oriented stock; HCAT is a small-cap quality compounder stock. DH pays a dividend while HCAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

DH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 45%
  • Dividend Yield > 1.2%
Run This Screen
Stocks Like

HCAT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 29%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DH and HCAT on the metrics below

Revenue Growth>
%
(DH: -5.5% · HCAT: -6.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.